QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Myriad Genetics
(NASDAQ:MYGN)
21.97
0.43[2.00%]
At close: May 20
21.97
00
After Hours: 4:03PM EDT
Day High/Low21.08 - 22.01
52 Week High/Low18.98 - 36.95
Open / Close21.84 / 21.97
Float / Outstanding55.5M / 80.3M
Vol / Avg.428K / 562K
Mkt Cap1.8B
P/E-
50d Avg. Price23.23
Div / Yield-
Payout Ratio-
EPS-0.26
Total Float55.5M

Myriad Genetics (NASDAQ:MYGN), Quotes and News Summary

Myriad Genetics (NASDAQ: MYGN)

Day High/Low21.08 - 22.01
52 Week High/Low18.98 - 36.95
Open / Close21.84 / 21.97
Float / Outstanding55.5M / 80.3M
Vol / Avg.428K / 562K
Mkt Cap1.8B
P/E-
50d Avg. Price23.23
Div / Yield-
Payout Ratio-
EPS-0.26
Total Float55.5M
Benzinga - May 5, 2022, 12:25PM
Benzinga - May 5, 2022, 9:06AM
Benzinga - May 5, 2022, 9:05AM
Benzinga - Apr 19, 2022, 10:15AM
Benzinga - Apr 1, 2022, 4:29PM
Benzinga - Mar 14, 2022, 7:08AM
Benzinga - Mar 14, 2022, 6:32AM
Benzinga - Feb 24, 2022, 9:10AM
Benzinga - Feb 23, 2022, 5:43PM
Benzinga - Dec 14, 2021, 4:07PM
Benzinga - Nov 3, 2021, 5:34AM
Benzinga - Nov 2, 2021, 8:32AM
Benzinga - Sep 7, 2021, 9:21AM
Benzinga - Aug 9, 2021, 8:31AM
Benzinga - Aug 3, 2021, 1:34PM
Benzinga - Aug 3, 2021, 1:09PM
load more
Sector: Health Care.Industry: Biotechnology
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-02
REV
Q1 2022Est.ActualSurprise
EPS-0.070-0.030 0.0400
REV156.620M164.900M8.280M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Myriad Genetics Questions & Answers

Q
How do I buy Myriad Genetics (MYGN) stock?
A

You can purchase shares of Myriad Genetics (NASDAQ: MYGN) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Myriad Genetics's (MYGN) competitors?
Q
What is the target price for Myriad Genetics (MYGN) stock?
A

The latest price target for Myriad Genetics (NASDAQ: MYGN) was reported by SVB Leerink on Thursday, May 5, 2022. The analyst firm set a price target for 26.00 expecting MYGN to rise to within 12 months (a possible 18.34% upside). 5 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Myriad Genetics (MYGN)?
A

The stock price for Myriad Genetics (NASDAQ: MYGN) is $21.97 last updated May 20, 2022, 8:00 PM UTC.

Q
Does Myriad Genetics (MYGN) pay a dividend?
A

There are no upcoming dividends for Myriad Genetics.

Q
When is Myriad Genetics (NASDAQ:MYGN) reporting earnings?
A

Myriad Genetics’s Q2 earnings are confirmed for Tuesday, August 2, 2022.

Q
Is Myriad Genetics (MYGN) going to split?
A

There is no upcoming split for Myriad Genetics.

Q
What sector and industry does Myriad Genetics (MYGN) operate in?
A

Myriad Genetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.